Cough, sarcoidosis and idiopathic pulmonary fibrosis: raw nerves and bad vibrations

Harrison, N K

doi:10.1186/1745-9974-9-9

Cited by 28 publications

(26 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no effect on QoL and survival was found and possible side-effects should be taken into consideration. Although opiates are recommended in the palliative setting, their effect has not been proven in IPF [1,27]. Caution is warranted as opiates may influence the protective mechanism of cough, but might be a useful option for palliation of severe cough in patients with advanced IPF.…”

Section: Treatment Of Cough In Ipfmentioning

confidence: 99%

“…Moreover, this is in line with clinical findings that patients often report starting to cough when talking or not being able to stop coughing once they start. The transmission of vibration caused by talking or even coughing itself might lead to increased mechanical stimulation of the sensory receptors, perpetuating a cycle of more cough and more vibration [27].…”

Section: Pathophysiology Of Cough In Ipfmentioning

confidence: 99%

“…1: traction leading to a weaker lower oesophageal sphincter tonus [45]; 2: microaspiration inducing epithelial damage [38,46]; 3: restriction inducing instability of the upper airway [39]; 4: intermitted hypoxaemia promoting profibrotic mechanisms [49]; 5: increased cough reflex sensitivity [22][23][24][25][26][27][28][29][30][31]; 6: pressure causing stretch injury and activation of fibrotic mechanisms [31]; 7: microaspiration causing an inflammatory reaction blocking the airway [53]; 8: obstruction increasing trans-diaphragmatic pressure [51,52]; 9: aspiration directly and acid reflux indirectly stimulate the cough reflex [6,47]; 10: cough increasing trans-diaphragmatic pressure [47]; 11: less central inhibition and inflammation increasing cough reflex sensitivity [54]. sensory nerves.…”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Cough in idiopathic pulmonary fibrosis

et al. 2016

View full text Add to dashboard Cite

Many patients with idiopathic pulmonary fibrosis (IPF) complain of chronic refractory cough. Chronic cough is a distressing and disabling symptom with a major impact on quality of life. During recent years, progress has been made in gaining insight into the pathogenesis of cough in IPF, which is most probably "multifactorial" and influenced by mechanical, biochemical and neurosensory changes, with an important role for comorbidities as well. Clinical trials of cough treatment in IPF are emerging, and cough is increasingly included as a secondary end-point in trials assessing new compounds for IPF. It is important that such studies include adequate end-points to assess cough both objectively and subjectively. This article summarises the latest insights into chronic cough in IPF. It describes the different theories regarding the pathophysiology of cough, reviews the different methods to assess cough and deals with recent and future developments in the treatment of cough in IPF. @ERSpublications Latest insights into pathophysiology of cough, methods to assess cough and developments in treatment of cough in IPF http://ow.ly/YfVAH

show abstract

Section: Treatment Of Cough In Ipfmentioning

confidence: 99%

Section: Pathophysiology Of Cough In Ipfmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Cough in idiopathic pulmonary fibrosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The prevalence of cough has been estimated to be between 3-53 %: Japan 3 %, Finland 33 %, Saudi Arabia 40 %, United Kingdom 50 % and Turkey 53 % [9]. Cough is more prevalent in female patients compared to males [9].…”

Section: Cough: Epidemiology and Mechanismsmentioning

confidence: 98%

Cough in Sarcoidosis

Tully

Birring

2015

Lung

View full text Add to dashboard Cite

Sarcoidosis is a granulomatous disorder that frequently affects the lungs. Cough is commonly reported by patients and can significantly reduce health-related quality of life. The mechanism of cough is unknown but airway inflammation, mechanical distortion from pulmonary fibrosis and disruption of the vagus nerve are possible. Recent evidence suggests cough reflex hypersensitivity may also be an important mechanism and predictor of the frequency of cough. The investigation of cough should evaluate common causes such as asthma, gastro-oesophageal reflux and rhinitis. In patients with suspected cough due to sarcoidosis, a trial of corticosteroids should be considered. The severity of cough should be evaluated with validated outcome measures such as visual analogue scales, cough severity diary, health-related quality of life questionnaires such as the Leicester Cough Questionnaire and objective cough monitors. Future studies are needed to identify targets for therapeutic development.

show abstract

“…Corticosteroids have been shown to improve cough in one small RCT and may be used at a tapering dose if beneficial (34). Opiates may be used in a palliative setting but there is no evidence for their effectiveness in IPF for cough suppression (42). The use of pirfenidone has been shown to have a possible beneficial effect on cough in a subgroup population of IPF patients (19).…”

Section: Coughmentioning

confidence: 99%

Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age

Shaw¹,

Marshall²,

Morris³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is the most common cause of interstitial lung disease (ILD) and carries a worse prognosis than many cancers. Until recently, there were no active treatment options available for patients with IPF, meaning palliation or lung transplantation in selected patients were the only options. The management of IPF has changed dramatically over the last decade with the advent of two antifibrotic agents; pirfenidone and nintedanib. These new agents have been shown to reduce decline in lung function and pirfenidone has been shown to reduce mortality. The changing landscape of IPF diagnosis and management present a number of issues that may be encountered including management of side effects related to antifibrotic therapy. This article aims to give an overview of the holistic approach to the management of patients with IPF, including antifibrotic management, symptom management and the invaluable role of the ILD specialist nurse.

show abstract

Cough, sarcoidosis and idiopathic pulmonary fibrosis: raw nerves and bad vibrations

Cited by 28 publications

References 38 publications

Cough in idiopathic pulmonary fibrosis

Cough in idiopathic pulmonary fibrosis

Cough in Sarcoidosis

Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age

Contact Info

Product

Resources

About